TAOX — TAO Synergies Share News
0.000.00%
Last trade - 00:00- $25.07m
- $22.70m
- $0.30m
Factbox: Eisai-Biogen Alzheimer's drug success follows many failures
Factbox: Eisai-Biogen Alzheimer's drug success follows many failures
Brief: Synaptogenix Announces Changes To Scientific Advisory Board In Preparation For Phase 2 Data
Brief: Synaptogenix Advances Dosing Of Patient In Dose Optimization Clinical Trial In Preparation For Phase 2 Alzheimer's Trial Data
NASDAQ RESUMED AT 09:44 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:39 AM
NASDAQ RESUMED AT 09:49 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:40 AM
Brief: Synaptogenix Completes Patient Enrollment In NIH Sponsored Phase 2B Alzheimer's Disease Trial
Brief: Synaptogenix Inc Files For Mixed Shelf Of Up To $100 Million
Synaptogenix rises as Maxim initiates with 'buy'
Brief: Synaptogenix Moves Forward With Clinical Development Plans For Bryostatin-1 As Treatment For Multiple Sclerosis
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:46 AM
Brief: Alpha Capital Anstalt Reports 5.49% Passive Stake In Synaptogenix
Synaptogenix rises on patent award for treating Alzheimer's
Brief: Synaptogenix Announces Regenerative Patent Award To Treat Alzheimer's Disease
NASDAQ RESUMED AT 01:36 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:31 PM
U.S. STOCKS ON THE MOVE-Nvidia, Enphase Energy, Gatos Silver, Nov, Peabody Energy